Manufacturing Chemist: GLP-1 based drug packaging

This article reviews trends related to GLP-1-type pharmaceuticals and discusses considerations for fill-and-finish and primary packaging containers. The development of glucagon-like peptide-1(GLP-1) drugs for type 2 diabetes and obesity has brought hope to patients in terms of improving their health and quality of life. The new molecular entities in clinical trials may bring even better treatments for these and other diseases. Although some of these drugs come in oral dosage form, most are administered by subcutaneous injection.The primary container for injectable drugs — whether vial, cartridge or syringe — is crucial to maintain drug safety and efficacy through filling, storage and administration.